Eli Lilly (LLY) is a pharmaceutical company that focuses on cardiometabolic health, neuroscience, oncology, and immunology.

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on ...

Drinking a cup or two of coffee every day may help you live longer -- but only if you skip the heavy cream and sugar, new ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Global shares are mostly higher and oil prices have slipped as investors await a decision on interest rates by the Federal Reserve. The inflation-fighters at the Fed are expected to ...

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...